Targeting Lysine Demethylase 5 (KDM5) in Mantle Cell Lymphoma. Targeting Lysine Demethylase 5 (KDM5) in Mantle Cell Lymphoma

Loss of function mutations in the histone methyltransferase KMT2D are common in lymphomas but difficult to target. We reported targeting KDM5 restores epigenetic balance in germinal centre (GC) lymphomas. Here, we show the KDM5 family are over-expressed in mantle cell lymphoma (MCL). GS716054, a pro-drug, increases H3K4 trimethylation (H3K4me3) and kills MCL cells including TP53 mutated cells via suppression of the MYC pathway. It can overcome ibrutinib resistance and synergises with ibrutinib. These data suggest a possible role for KDM5-inhibitors in advanced MCL. Overall design: 3 celllines were treated with either control (DMSO) or KDM5 inhibitor (GS716054) and RNAseq was performed after 24 or 72 hours post treatment.